Progenics Pharmaceut (PGNX) 5.84 $PGNX Progenics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Progenics Pharmaceut (PGNX) 5.84 $PGNX

Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR(R) Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain
GlobeNewswire - Tue Jul 26, 7:30AM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX) announced today that it has received a $50 million milestone payment from its worldwide collaboration partner, Valeant Pharmaceuticals International, Inc. (NYSE:VRX), resulting from the US Food and Drug Administration's marketing approval last week of RELISTOR Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
PGNX: 5.84 (-0.01), VRX: 20.89 (-1.41)

After Yesterday's Decline of 3.86%, Progenics Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 13, 3:27PM CDT
Progenics Pharmaceuticals (NASDAQGNX) traded in a range yesterday that spanned from a low of $4.89 to a high of $5.20. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $5.16 on volume of 651,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PGNX: 5.84 (-0.01)

Progenics Pharmaceuticals (PGNX) Jumps: Stock Up 9.3%
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:15AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) shares rose over 9% in the last trading session.
MNK: 67.37 (+0.03), PGNX: 5.84 (-0.01)

Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform
BusinessWire - Tue Jun 21, 7:30AM CDT
Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today that Progenics Pharmaceuticals, Inc. (NasdaqGNX) has entered into a commercial license agreement for the use of Selexis' technology and proprietary CHO-K1 cell line.
PGNX: 5.84 (-0.01)

Commit To Purchase Progenics Pharmaceuticals At $4, Earn 20.7% Annualized Using Options
StockOptionsChannel.com - Mon Jun 20, 10:37AM CDT
Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $4.77/share, might benefit from considering selling puts among the alternative strategies at their disposal.
PGNX: 5.84 (-0.01)

Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.84 (-0.01), BIIB: 301.83 (+11.90), VVUS: 1.05 (-0.02), PTCT: 6.10 (+0.13)

Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX) announced today that data from its 1404 and PyL prostate cancer imaging programs will be presented at the upcoming Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting, taking place from June 11 - 15, 2016 in San Diego, California.
PGNX: 5.84 (-0.01)

Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases.
PGNX: 5.84 (-0.01), FOLD: 6.71 (-0.01)

Progenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 11:30 a.m. Eastern Time. The conference is being held at the Grand Hyatt in New York, NY.
PGNX: 5.84 (-0.01)

Progenics reports 1Q loss
Automated Insights - Thu May 05, 8:48AM CDT
TARRYTOWN, N.Y. (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $12.7 million in its first quarter.
PGNX: 5.84 (-0.01)

Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
GlobeNewswire - Thu May 05, 6:30AM CDT
-- On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics' PSMA Antibody Technology In Combination with Alpha-Emitting Radionuclides
PGNX: 5.84 (-0.01)

Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled Therapeutic Antibodies
GlobeNewswire - Mon May 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX) today announced that it has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Company's prostate specific membrane antigen (PSMA) antibody technology with Bayer's targeted thorium conjugate technology.
PGNX: 5.84 (-0.01)

Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2016 financial results on Thursday, May 5, 2016, at 8:30 a.m. ET.
PGNX: 5.84 (-0.01)

Market Exclusive Research Weekly Biotech Report
ACCESSWIRE - Mon Apr 18, 8:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.
PGNX: 5.84 (-0.01), CLVS: 15.04 (+0.76), SRPT: 25.91 (+0.63), COLL: 11.86 (-0.27), CHMA: 2.70 (+0.05)

Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 4:00PM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, CEO, is scheduled to present at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 8:40 a.m. Eastern Time. The conference is being held at The Westin Grand Central Hotel in New York, NY.
PGNX: 5.84 (-0.01)

Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
PR Newswire - Mon Apr 04, 6:00AM CDT
Agency requests standard three-month extension to review additional solicited information-
PGNX: 5.84 (-0.01), VRX: 20.89 (-1.41), VRX.TO: 29.08 (-1.37)

Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 5.84 (-0.01), BIND: 0.78 (-0.09), MNKD: 1.02 (+0.03), KERX: 4.72 (-2.64)

Progenics Pharmaceuticals to Present at 28th Annual ROTH Conference
GlobeNewswire - Wed Mar 09, 4:00PM CST
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative ways to target and treat cancer, announced today that Mark R. Baker, CEO, will present at the 28 Annual ROTH Conference in Dana Point, CA on Wednesday March 16, 2016 at 9:30 a.m. Pacific Time.
PGNX: 5.84 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 222

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 202

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 86

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 41

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 177

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 94

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Labcorp's Brazil Trial Push Has Promise and Plenty to Prove

Updated Category News Views 93

Brazilian clinical-trial kit deliveries may soon spend less time tangled in international shipping. That is the practical heart of Labcorp's newly announced collaboration with Grupo Fleury, and frankly, practical is plenty good in this business. Labcorp plans to begin assembling clinical-trial kits locally in Brazil in early 2027, then add laboratory operations by the end...

Continue Reading

Top 5 Most Recently Viewed Articles

Hormel Foods Welcomes Debbra Schoneman to Board of Directors

Updated Category News Views 77

Debbra Schoneman Joins Hormel Foods Board of Directors Hormel Foods Corporation (NYSE: HRL), a leader in the global branded food sector, is excited to announce the election of Debbra Schoneman to its Board of Directors. This pivotal decision aligns with the company's ongoing dedication to excellence and innovative leadership. Debbra Schoneman's Background Jim Snee, the...

Continue Reading
Superorganism Secures $25.9M for Biodiversity Ventures

Updated Category News Views 182

Superorganism Secures $25.9M for Biodiversity Ventures Nature and technology fund backed by leading investors aims to redefine how capital advances biodiversity Superorganism, a pioneering venture capital firm focusing on technology solutions for biodiversity, recently announced the successful closure of its debut fund, garnering commitments amounting to $25.9 million....

Continue Reading
Teamsters Local 838 Welcomes First Student Workers in Missouri

Updated Category News Views 174

Teamsters Local 838 Welcomes First Student Workers In a significant development for school transportation workers, more than 100 bus drivers and monitors at First Student in Missouri have united under Teamsters Local 838. This successful vote marks a substantial step in expanding Teamster representation within the school transportation sector, ensuring these workers have...

Continue Reading
Exploring Promising Tech Innovators: Beyond the Giants

Updated Category News Views 121

Understanding the Tech Landscape The technology sector has captured the spotlight as one of the leading areas of growth in recent times. Yet, within this vast landscape, not all players enjoy the same level of success. Many people automatically think of established giants when they hear "tech"—companies often dubbed as the Magnificent Seven, including major players such...

Continue Reading
Highland Copper Innovates with New Drilling and Flotation Tech

Updated Category News Views 112

Highland Copper's New Drilling Program for Metallurgy Highland Copper Company Inc. is taking an exciting step forward with a new drilling program aimed at exploring and optimizing its mining operations. This initiative demonstrates Highland Copper's dedication to utilizing innovative and sustainable mining methods, significantly enhancing its project economics. Focusing...

Continue Reading